Sugi Predict

Sugi Predict / Targets / SCARB1

SCARB1

Scavenger receptor class B member 1 · Q8WTV0 · SCARB1 on Sugi Atlas →

2,567 patent compounds predicted against SCARB1, 1,306 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL4204690 SCHEMBL4204690 1.00 20/20
SCHEMBL4200388 SCHEMBL4200388 0.73 20/20
SCHEMBL4026174 SCHEMBL4026174 1.00 19/20
SCHEMBL4192942 SCHEMBL4192942 1.00 19/20
SCHEMBL4205318 SCHEMBL4205318 0.73 19/20
SCHEMBL4205587 SCHEMBL4205587 0.73 19/20
SCHEMBL4024715 SCHEMBL4024715 0.73 19/20
SCHEMBL4193427 SCHEMBL4193427 0.81 18/20
SCHEMBL4033003 SCHEMBL4033003 0.80 18/20
SCHEMBL4211410 SCHEMBL4211410 0.55 18/20
SCHEMBL4029779 SCHEMBL4029779 0.82 17/20
SCHEMBL4195163 SCHEMBL4195163 0.80 17/20
SCHEMBL4201950 SCHEMBL4201950 0.66 17/20
SCHEMBL4195391 SCHEMBL4195391 0.72 16/20
SCHEMBL4023232 SCHEMBL4023232 0.69 16/20
SCHEMBL4028735 SCHEMBL4028735 0.79 15/20
SCHEMBL4032075 SCHEMBL4032075 0.75 15/20
SCHEMBL1600950 SCHEMBL1600950 0.73 15/20
SCHEMBL4410331 SCHEMBL4410331 0.68 15/20
SCHEMBL4410336 SCHEMBL4410336 0.68 15/20

Clinical trials — most relevant to SCARB1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Endometriosis and Microvascular Dysfunction; Simvastatin and Duavee PHASE4RECRUITING
Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon PHASE4COMPLETED
Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons PHASE4COMPLETED
Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes PHASE3COMPLETED
A Study Comparing the Mechanisms of Action of Lifibrol and Pravastatin PHASE3COMPLETED
Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia PHASE3COMPLETED
Treatment of Severe Infection With Antihyperlipidemia Drug PHASE2/PHASE3UNKNOWN
SR-BI and Antiviral Treatment Response in HCV nanCOMPLETED
The Association of SAA With Apolipoprotein B Affects Cardiovascular Risk nanCOMPLETED
The Influence of Food Matrix Delivery System on the Bioavailability of Vitamin D3 nanCOMPLETED
Mechanisms of Low Levels of Apolipoprotein B nanCOMPLETED
Genetics of Low Density Lipoprotein Subclasses in Hypercholesterolemia nanCOMPLETED
Genetic and Metabolism of Post-prandial HDL Particles nanCOMPLETED
Chronic Kidney Disease : Role of Biological Factors and Apolipoprotein L1 Encoding Gene (APOL1) nanCOMPLETED
Erythrocyte-bound Apolipoprotein B After Withdrawal of Statin Therapy nanCOMPLETED
Relation Among HDL Functionality, Neoatherosclerosis and Target Lesion Revascularization nanCOMPLETED
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children nanWITHDRAWN
Sex Hormones and Blood PCSK9 Levels nanCOMPLETED
Exercise and the Receptor for Advanced Glycation End Products (RAGE) nanCOMPLETED
Prospective Assessment of Atherosclerotic Cardiovascular Disease (ASCVD) Risk nanUNKNOWN
Identification of Donors of CD36-Deficient Platelets Among Japanese Individuals on the NIH Campus nanCOMPLETED
The Roles of SAH Gene Family in Athrogenic Dyslipidemia in Postmenopausal Women nanUNKNOWN
Relationship of Haptoglobin Phenotype to Vascular Function and Response to Vitamin E Supplementation in Patients With Diabetes Mellitus Type 2: The EVAS Trial nanUNKNOWN
Influence of Simvastatin on Apolipoprotein B-100 (apoB-100) Secretion nanCOMPLETED
Impact of Subclinical Hypothyroidism on Liver Enzymes and Lipid Profile nanNOT_YET_RECRUITING
Biomarker for Homozygous Familial Hypercholesterolemia (BioHoFH) nanWITHDRAWN
Epidemiology of Atherosclerosis nanCOMPLETED
Role of the Inflammatory Receptors in the Pathogenesis of Atherosclerosis nanUNKNOWN
Cardiac Biomarkers in Preeclampsia: Prediction of Disease and the Risk of Future Cardiovascular Events in Survivors nanUNKNOWN
In Vitro Demonstration of Direct Platelet-Related Effects of PCSK9 Enzyme nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a SCARB1 binder may also engage these)

ProteinNameSimilarity
Q61009 — 0.986 Q61009 →
Q60417 — 0.983 Q60417 →
Q8SQC1 — 0.981 Q8SQC1 →
O18824 — 0.981 O18824 →
P97943 — 0.977 P97943 →
P2RX2 P2X purinoceptor 2 0.943 landscape →
Q8K3P1 — 0.942 Q8K3P1 →
Q708S5 — 0.942 Q708S5 →
P18916 — 0.940 P18916 →
P04760 — 0.939 P04760 →
Q92075 — 0.939 Q92075 →
Q61180 — 0.938 Q61180 →
Q708S3 — 0.938 Q708S3 →
Q6NXK8 — 0.938 Q6NXK8 →
Q9R1N2 — 0.937 Q9R1N2 →
P37089 — 0.937 P37089 →
P49653 — 0.935 P49653 →
Q95165 — 0.935 Q95165 →
P25109 — 0.934 P25109 →
O97742 — 0.934 O97742 →
O70397 — 0.934 O70397 →
Q98864 — 0.934 Q98864 →
CHRNB1 Acetylcholine receptor subunit beta 0.933 landscape →
Q5MNU5 — 0.933 Q5MNU5 →
K7GET2 — 0.933 K7GET2 →
P04758 — 0.933 P04758 →
O62816 — 0.932 O62816 →
P02713 — 0.932 P02713 →
P37090 — 0.931 P37090 →
A6QM06 — 0.931 A6QM06 →